Alphamab Oncology Unveils Promising Preclinical Results for JSKN021 and JSKN022

The latest update is out from Alphamab Oncology ( (HK:9966) ).

Alphamab Oncology announced the presentation of research updates on their preclinical activities for JSKN021 and JSKN022 at the 2025 AACR Annual Meeting. JSKN021, a dual payload ADC targeting EGFR/HER3, demonstrated strong tumor inhibition and stability in preclinical studies, showing potential to overcome resistance in cancer treatments. JSKN022, targeting PD-L1 and ITGB6/8, exhibited enhanced tumor suppression and stability, indicating its promise as a multi-specific ADC for cancer therapy. These advancements highlight Alphamab’s commitment to developing next-generation cancer treatments with improved efficacy and reduced toxicity.

More about Alphamab Oncology

Alphamab Oncology is a biotechnology company focused on the development of innovative cancer therapies. The company specializes in creating antibody-drug conjugates (ADCs) targeting specific cancer antigens to address tumor heterogeneity and resistance to current treatments.

YTD Price Performance: 94.86%

Average Trading Volume: 5,414,430

Technical Sentiment Signal: Sell

Current Market Cap: HK$6.58B

See more insights into 9966 stock on TipRanks’ Stock Analysis page.